Chester County News and Community Website
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) granted stock options covering 146,000 shares to a newly hired employee under a Nasdaq inducement award provision, a compensation mechanism commonly used …
Context Therapeutics Grants New-Hire Equity Award Under Nasdaq Rule Read More PHILADELPHIA, PA — Context Therapeutics (Nasdaq: CNTX) amended its licensing agreement with BioAtla (Nasdaq: BCAB) to eliminate future milestone and royalty payments tied to its CT-202 cancer program, a move …
Context Therapeutics Buys Out CT-202 Royalty Obligations Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) expects interim clinical data from two experimental cancer therapies later this year as the biotechnology company advances multiple bispecific antibody programs targeting …
Context Therapeutics Advances Cancer Drug Pipeline Toward Data Readouts Read More PHILADELPHIA, PA — Context Therapeutics Inc. (NASDAQ: CNTX) said it has granted non-qualified stock option awards covering a total of 120,000 shares of common stock to two newly hired employees …
Context Therapeutics (NASDAQ: CNTX) Issues Equity Awards to Attract New Talent Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) reported third-quarter 2025 financial results and provided an update on its pipeline of bispecific T cell engager (TCE) programs, highlighting early signs …
Context Therapeutics Reports Encouraging Early Data in Cancer Trials, Eyes 2026 Milestones Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced it will present at two upcoming investor conferences in November, highlighting its growing pipeline of T cell–engaging bispecific antibodies for solid …
Context Therapeutics to Showcase Cancer Immunotherapy Advances at Investor Events Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced that it will present new clinical and preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking …
Context Therapeutics to Present New Data on Two Bispecific T Cell Engagers at SITC 2025 Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced it has granted stock options to purchase 30,000 shares of common stock to a newly hired employee as part of an …
Context Therapeutics Grants Stock Options to New Hire Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced that it will participate in two major investor conferences in September.
Context Therapeutics to Present at Upcoming Investor Conferences Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biotechnology company advancing T cell-engaging bispecific antibodies for solid tumors, reported a second-quarter net loss of $8.8 million as it continues …
Context Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2 Read More